206 related articles for article (PubMed ID: 32939574)
1. Patient perspectives on the therapeutic profile of botulinum neurotoxin type A in cervical dystonia.
Comella C; Ferreira JJ; Pain E; Azoulai M; Om S
J Neurol; 2021 Mar; 268(3):903-912. PubMed ID: 32939574
[TBL] [Abstract][Full Text] [Related]
2. Patient Perspectives on the Therapeutic Profile of Botulinum Neurotoxin Type A in Spasticity.
Jacinto J; Varriale P; Pain E; Lysandropoulos A; Esquenazi A
Front Neurol; 2020; 11():388. PubMed ID: 32477251
[No Abstract] [Full Text] [Related]
3. Botulinum Toxin Utilization, Treatment Patterns, and Healthcare Costs Among Patients with Spasticity or Cervical Dystonia in the US.
Hull M; Anupindi VR; DeKoven M; He J; Bouchard J
Adv Ther; 2023 Sep; 40(9):3986-4003. PubMed ID: 37414904
[TBL] [Abstract][Full Text] [Related]
4. The impact of the initial severity on later outcome: retrospective analysis of a large cohort of botulinum toxin naïve patients with idiopathic cervical dystonia.
Hefter H; Samadzazeh S; Rosenthal D
J Neurol; 2021 Jan; 268(1):206-213. PubMed ID: 32761340
[TBL] [Abstract][Full Text] [Related]
5. The clinical utility of botulinum toxin injections targeted at the motor endplate zone in cervical dystonia.
Delnooz CC; Veugen LC; Pasman JW; Lapatki BG; van Dijk JP; van de Warrenburg BP
Eur J Neurol; 2014 Dec; 21(12):1486-e98. PubMed ID: 25060697
[TBL] [Abstract][Full Text] [Related]
6. The Impact of the Course of Disease before Botulinum Toxin Therapy on the Course of Treatment and Long-Term Outcome in Cervical Dystonia.
Hefter H; Schomaecker I; Schomaecker M; Rosenthal D; Samadzadeh S
Toxins (Basel); 2021 Jul; 13(7):. PubMed ID: 34357965
[TBL] [Abstract][Full Text] [Related]
7. INTEREST IN CD2, a global patient-centred study of long-term cervical dystonia treatment with botulinum toxin.
Misra VP; Colosimo C; Charles D; Chung TM; Maisonobe P; Om S;
J Neurol; 2018 Feb; 265(2):402-409. PubMed ID: 29270685
[TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin and conservative treatment strategies in people with cervical dystonia: an online survey.
Boyce MJ; McCambridge AB; Bradnam LV; Canning CG; De Oliveira CQ; Verhagen AP
J Neural Transm (Vienna); 2024 Jan; 131(1):43-51. PubMed ID: 37831150
[TBL] [Abstract][Full Text] [Related]
9. The barriers and facilitators to satisfaction with botulinum neurotoxin treatment in people with cervical dystonia: a systematic review.
Boyce MJ; McCambridge AB; Bradnam LV; Canning CG; Verhagen AP
Neurol Sci; 2022 Aug; 43(8):4663-4670. PubMed ID: 35593979
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
Pappert EJ; Germanson T;
Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
[TBL] [Abstract][Full Text] [Related]
11. Exploring the Interplay between the Clinical and Presumed Effect of Botulinum Injections for Cervical Dystonia: A Pilot Study.
Hefter H; Samadzadeh S
Toxins (Basel); 2023 Sep; 15(10):. PubMed ID: 37888623
[TBL] [Abstract][Full Text] [Related]
12. KinesioTaping after botulinum toxin type A for cervical dystonia in adult patients.
Dec-Ćwiek M; Porębska K; Sawczyńska K; Kubala M; Witkowska M; Zmijewska K; Antczak J; Pera J
Brain Behav; 2022 Apr; 12(4):e2541. PubMed ID: 35238494
[TBL] [Abstract][Full Text] [Related]
13. Changes in sensorimotor network activation after botulinum toxin type A injections in patients with cervical dystonia: a functional MRI study.
Nevrlý M; Hluštík P; Hok P; Otruba P; Tüdös Z; Kaňovský P
Exp Brain Res; 2018 Oct; 236(10):2627-2637. PubMed ID: 29971454
[TBL] [Abstract][Full Text] [Related]
14. The dystonia discomfort scale (DDS): a novel instrument to monitor the temporal profile of botulinum toxin therapy in cervical dystonia.
Dressler D; Kupsch A; Seitzinger A; Paus S
Eur J Neurol; 2014 Mar; 21(3):459-62. PubMed ID: 24433495
[TBL] [Abstract][Full Text] [Related]
15. Botulinum toxin type B for cervical dystonia.
Costa J; Espírito-Santo C; Borges A; Ferreira JJ; Coelho M; Moore P; Sampaio C
Cochrane Database Syst Rev; 2005 Jan; (1):CD004315. PubMed ID: 15674941
[TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin type A and cervical dystonia: a seven-year follow-up.
Camargo CH; Teive HA; Becker N; Munhoz RP; Werneck LC
Arq Neuropsiquiatr; 2011 Oct; 69(5):745-50. PubMed ID: 22042174
[TBL] [Abstract][Full Text] [Related]
17. Botulinum Neurotoxin Therapy for Lingual Dystonia Using an Individualized Injection Method Based on Clinical Features.
Yoshida K
Toxins (Basel); 2019 Jan; 11(1):. PubMed ID: 30658420
[TBL] [Abstract][Full Text] [Related]
18. Botulinum Toxin Type A Injection for Cervical Dystonia in Adults with Dyskinetic Cerebral Palsy.
Yi YG; Kim K; Yi Y; Choi YA; Leigh JH; Bang MS
Toxins (Basel); 2018 May; 10(5):. PubMed ID: 29772695
[TBL] [Abstract][Full Text] [Related]
19. Effect of Botulinum Toxin on Non-Motor Symptoms in Cervical Dystonia.
Costanzo M; Belvisi D; Berardelli I; Maraone A; Baione V; Ferrazzano G; Cutrona C; Leodori G; Pasquini M; Conte A; Fabbrini G; Defazio G; Berardelli A
Toxins (Basel); 2021 Sep; 13(9):. PubMed ID: 34564651
[TBL] [Abstract][Full Text] [Related]
20. Subjective versus objective symptom intensities ratings in cervical dystonia and hemifacial spasm across a botulinum neurotoxin cycle.
Wöllner J; Weise D; Leplow B
Brain Behav; 2021 Mar; 11(3):e02023. PubMed ID: 33403834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
